Saccharomyces boulardii Ameliorate the Inflammation in Ovalbumin-induced Atopic Dermatitis in Mice Model

Abstract

The current study aimed to investigate the immunomodulatory and anti-inflammatory role of Saccharomyces boulardii in Ovalbumin-induced Atopic Dermatitis (AD) in murine model. AD is a life-long disease so there is need for a therapy which uplifts the standard of living and reduce the side effects. The current treatment for AD has many limitations including compromised quality of life, low compliance, lack of cost effectiveness and reported adverse effects. The probiotic S. boulardii under study managed to reduce inflammation caused by allergen and AD progression by immune regulation and preventing barrier disfunction. The disease induced by ovalbumin was reversed by S. boulardii showing promising results through behavioral parameters, improvements in clinical scores and spleen index. Serum biochemistry, hematological parameters and serum IgE investigation by ELISA further showed reduction in inflammation in groups treated with probiotic. Histological examination revealed reduction in tissue infiltration, decreased collagen accumulation and infiltration of immune cells in treated groups as compared to the diseased group. The level of serum bilirubin and creatinine was measured along with the histological changes in liver and kidney to observe the effect of Dexamethasone (5 mg/kg) in mice model. Furthermore, TNF-α/NF-κB signaling pathway activated in AD was regulated in treatment groups and S. boulardii also maintained oxidant/antioxidant balance. This study concludes that S. boulardii could be an effective novel treatment for AD that could reduce inflammation with increased safety and improved quality of life.